OGEN - Oragenics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

Oragenics, Inc.

4902 Eisenhower Boulevard
Suite 125
Tampa, FL 33634
United States
813-286-7900
http://www.oragenics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Dr. Alan F. JoslynPres, CEO & Director504.7kN/A1959
Mr. Michael O. Sullivan CPACFO, Sec. & Treasurer298.39kN/A1956
Dr. Martin HandfieldSr. VP of Discovery Research240.59kN/A1971
Dr. Raman BediChairman of International Scientific Advisory Board and Sr. ConsultantN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring chemical agent for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013; a license agreement with LPThera LLC to develop LPT3-04; and a license agreement Texas A&M University System for access to new homologs of the lantibiotic MU1140 and other lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

Corporate Governance

Oragenics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.